Skip to main content

Table 4 Impact of ASD participants’ characteristics on serum endocannabinoid levels

From: Lower circulating endocannabinoid levels in children with autism spectrum disorder

  AEA OEA PEA
ADOS comparison score [R (P)]# 0.01 (0.9) 0.06 (0.5) 0.07 (0.4)
VABS standard score [R (P)]# − 0.02 (0.8) − 0.05 (0.6) 0.09 (0.4)
CARS summary score [R (P)]# − 0.15 (0.15) − 0.08 (0.3) − 0.03 (0.7)
DSM-5: level of support required in social communication [R (P)]# − 0.11 (0.29) 0.01 (0.89) 0.03 (0.9)
DSM-5: level of support required in repetitive restricted behavior [R (P)]# − 0.01 (0.9) 0.01 (0.89) − 0.01 (0.7)
CGI-S, behavior [R (P)]# − 0.09 (0.3) 0.05 (0.2) 0.13 (0.2)
CGI-S, anxiety [R (P)]# 0.08 (0.8) 0.11 (0.6) 0.07 (0.4)
Family history of ASD [yes/no; χ2 (P)]# 1.13 (0.6) 0.11 (0.73) 1.05 (0.58)
Perinatal complications [yes/no; χ2 (P)]# 0.02 (0.8) 0.53 (0.4) 0.44 (0.8)
Epilepsy comorbidity [yes/no; χ2 (P)]# 0.26 (0.6) 0.64 (0.42) 2.18 (0.3)
ADHD [yes/no; χ2 (P)]# 1.84 (0.07) 1.12 (0.26) 1.5 (0.13)
Medications
 Any [yes/no; χ2 (P)]# 1.71 (0.19) 1.45 (0.2) 3.51 (0.17)
 Antipsychotic [number; R (P)]# 0.18 (0.07) 0.14 (0.17) 0.02 (0.8)
 SSRIs [yes/no; χ2 (P)]# 0.13 (0.7) 0.68 (0.7) 0.48 (0.7)
 Stimulants [yes/no; χ2 (P)]# 0.93 (0.6) 0.94 (0.3) 2.10 (0.3)
 Antiepileptic [yes/no; χ2 (P)]# 0.45 (0.5) 0.58 (0.45) 0.81 (0.37)
HSQ total score [R (P)]# 0.07 (0.5) − 0.04 (0.7) 0.03 (0.8)
APSI—total score [R (P)]# − 0.19 (0.06) − 0.03 (0.7) 0.08 (0.4)
Parents SRS—t score [R (P)]# − 0.48 (0.6) 0.06 (0.3) − 0.08 (0.4)
CBCL—externalizing score [R (P)]# 0.04 (0.6) 0.12 (0.2) 0.08 (0.4)
SCQ—summary score [R (P)]# − 0.02 (0.8) 0.05 (0.6) 0.01 (0.8)
  1. #Results are presented as Pearson correlation coefficient R, (P value) for continuous variables and as Pearson chi-square χ2 (P value) for dichotomous variables (AEA, OEA, PEA cut-off levels)